首页> 外文期刊>Vojnosanitetski Pregled >Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction
【24h】

Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction

机译:急性心肌梗死患者使用阿替普酶和链激酶治疗后的冠状动脉血流和出血并发症

获取原文
           

摘要

Background/Aim. Up-to-date treatment of acute myocardial infarction (AIM) has been based on as early as possible establishment of circulation in ischemic myocardium whether by the use of fibrinolythic therapy and/or urgent coronary intervention which significantly changes the destiny of patients with AMI, but also increases the risk of bleeding. The aim of this study was to compare coronary flow and bleeding complications in patients with acute myocardial infarction with ST-elevation (STEMI) after administration of alteplase or streptokinase. Methods. The study included 254 patients with STEMI. The group I (n = 174) received streptokinase, and the group II (n = 80) received alteplase. We followed frequency of complications such as bleeding and hypotension in the investigated groups of patients, based on the TIMI classification of bleeding, as well as the transience of infarction artery in accordance with TIMI flow. Results. The patients with myocardial infarction after administration of alteplase had statistically significantly higher coronary flow (TIMI- 3), 72.5% as compared to the patients who received streptokinase, 39.2%. Hypotension as complication of fibrynolythic therapy administration occurred in a significantly higher percentage in the group of patients who received streptokinase. There was no statistically significant difference in the appearance of major bleeding in the groups of patients who received streptokinasis and alteplase (6.9% and 7.5%, respectively). Also, there was no difference in the appearance of minor and minimal bleeding among the investigated groups of patients. Conclusion. It was shown that alteplase in a higher number of patients provided TIMI-3 coronary flow as compared to streptokinese. In comparison with streptokinase, a combination of alteplase, enoxaparin and double antiplatelet therapy enabled earlier achievement of coronary flow through previously blocked coronary artery that was more complete (higher frequency of TIMI-3 flow). There were no statistically significant difference in frequency of bleeding, first of all major bleeding, between the groups treated by alteplase and streptokinase.
机译:背景/目标。急性心肌梗死(AIM)的最新治疗是基于尽早建立缺血性心肌循环的基础,无论是通过使用纤溶蛋白疗法和/或紧急冠状动脉介入治疗,都可显着改变AMI患者的命运,而且还会增加出血的风险。这项研究的目的是比较阿替普酶或链激酶治疗后急性ST段抬高(STEMI)的急性心肌梗死患者的冠脉流量和出血并发症。方法。该研究包括254例STEMI患者。第一组(n = 174)接受链激酶,第二组(n = 80)接受阿替普酶。根据出血的TIMI分类以及根据TIMI流量的梗死动脉的瞬变,我们追踪了被调查患者组中出血和低血压等并发症的发生频率。结果。服用阿替普酶后发生心肌梗塞的患者与接受链激酶治疗的患者(39.2%)相比,冠状动脉血流量(TIMI-3)具有统计学上的显着提高(72.5%)。在接受链激酶治疗的患者组中,低血压作为纤溶酶疗法的并发症发生率高得多。在接受链激酶病和阿替普酶治疗的患者组中,大出血的出现无统计学差异(分别为6.9%和7.5%)。同样,在所研究的患者组中,轻微出血和最小出血的出现也没有差异。结论。结果显示,与链激酶相比,阿替普酶在更多患者中提供TIMI-3冠状动脉血流。与链激酶相比,阿替普酶,依诺肝素和双重抗血小板治疗的组合能够更早地通过先前阻塞的冠状动脉实现冠脉血流,而冠状动脉血流更为完整(TIMI-3血流频率更高)。在用阿替普酶和链激酶治疗的组之间,首先是大出血的出血频率没有统计学上的显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号